Indian pharmaceutical firm Dr Reddy’s has relocated its Chirotech subsidiary to a new, purpose-built facility within Cambridge Science Park in the UK.

The facility will provide small molecule manufacturing services for Dr Reddy’s and third-party pharmaceutical companies as part of its contracting business.

Dr Reddy’s CEO GV Prasad said: “The UK is an expensive location, but it has talent we could not attract in India. The UK is more appealing because of its ‘ecosystem’ of links to universities and biotech companies.”

The relocation comes as part of the company’s plans for growth of its custom pharma services business which also includes R&D centres and API manufacturing plants in India, Mexico and UK.